REDWOOD CITY, Calif.,
April 11, 2018 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings,
today reported the publication of a report commissioned by AcelRx
analyzing the economic burden associated with administration of
intravenous (IV) morphine for acute pain in the emergency
department (ED) in the peer-reviewed journal Drugs in
Context. This manuscript reports on the results of a
micro-costing analysis to estimate the burden of IV administration
of morphine in five key European countries based on a literature
review. The study estimated the total cost to administer IV
morphine ranged from €121 to €132 depending upon the country, when
including the cost of IV related complications, such as infection
or phlebitis. Conclusions of the study highlighted that the
costs associated with IV administration for moderate-to-severe
acute pain relief in the ED inflict an economic burden on national
health services; these costs could potentially be avoided with an
equally rapid and efficacious analgesic not requiring IV
administration.
"The use of IV morphine for the treatment of acute pain in the
emergency department poses a significant economic burden on health
systems," said Montserrat Casamayor, MD, PhD, senior medical writer
for QuintilesIMS and lead author on the study. "A non-invasive and
efficacious analgesic that circumvents the potential for IV-related
complications could reduce the financial strain on hospitals and
health centers."
Details on the publications:
Casamayor M, DiDonato K, Hennebert M, Brazzi L, Prosen G.
Administration of intravenous morphine for acute pain in the
emergency department inflicts an economic burden in Europe. Drugs in Context. 2018
April.
About the Journal:
Drugs in Context is an open access, peer-reviewed,
continuous publication of international standing. It is a member of
the Directory of Open Access Journals (https://doaj.org/). It is
listed on PubMed and all articles are free-to-view/download
immediately on PubMed Central. It publishes high-quality,
peer-reviewed original research papers and topical review articles
covering the latest evidence and innovations in drug treatment
across all therapeutic areas. In addition, it single-blinds
external peer review on all manuscripts with comments from at least
two peer reviewers.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of innovative
therapies for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
company has two product candidates including DSUVIA™ (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication
for the treatment of moderate-to-severe acute pain in medically
supervised settings, and Zalviso® (sufentanil sublingual tablet
system, SST system, 15 mcg) being developed as an innovatively
designed, patient-controlled analgesia (PCA) system for reduction
of moderate-to-severe acute pain in medically supervised
settings.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-announces-publication-analyzing-the-cost-of-administering-iv-morphine-for-acute-pain-in-emergency-departments-in-europe-300628115.html
SOURCE AcelRx Pharmaceuticals, Inc.